Skip to main content

Research Repository

Advanced Search

All Outputs (64)

Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia—a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial (2024)
Journal Article
Flett, L., Abdelatif, R., Akhtar Baz, S., Brady, S., Corbacho, B., Common, K., Cowling, A., Fairhurst, C., Fitzmaurice, E., Gandhi, S., Hilton, A., Hope, W., Howard, A., Laycock, J., Lillie, P., Mitchell, G., Parker, A., Peel, M., Sheard, L., Sneddon, J., …Barlow, G. (2024). Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia—a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial. Trials, 25(1), Article 427. https://doi.org/10.1186/s13063-024-08272-w

BACKGROUND: Acute leukaemias (AL) are life-threatening blood cancers that can be potentially cured with treatment involving myelosuppressive, multiagent, intensive chemotherapy (IC). However, such treatment is associated with a risk of serious infect... Read More about Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia—a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial.

Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population (2024)
Journal Article
Molica, S., Shanafelt, T. D., Allsup, D., & Giannarelli, D. (2024). Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population. Cancers, 16(6), Article 1085. https://doi.org/10.3390/cancers16061085

To assess the impact of first-line treatment with targeted agents (TAs) or fludarabine, cyclophosphamide, and rituximab (FCR)-based chemo-immunotherapy (CIT) on overall survival (OS) compared to age- and sex-matched individuals in the general populat... Read More about Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease (2023)
Journal Article
Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Walewska, R., Duley, L., Howard, D., …Hillmen, P. (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine, 390(4), 326-337. https://doi.org/10.1056/NEJMoa2310063

BACKGROUND: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration... Read More about Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials (2023)
Journal Article
Molica, S., & Allsup, D. (2023). Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials. Expert Review of Anticancer Therapy, https://doi.org/10.1080/14737140.2023.2288899

Introduction: Chronic lymphocytic leukemia (CLL) management has witnessed a transformative shift with the advent of time-limited venetoclax and anti-CD20 monoclonal antibody (mAb) regimens, as exemplified by the groundbreaking MURANO and CLL14 trials... Read More about Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials.

Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (in press). Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions. Hematological Oncology, https://doi.org/10.1002/hon.3238

In the modern era of Chronic Lymphocytic Leukemia (CLL) targeted therapy, the loss of p53 function due to genetic abnormalities remains a significant challenge. This is because even targeted agents, which are currently the mainstay of treatment for C... Read More about Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients (2023)
Presentation / Conference Contribution
Sarma, A., Evans, C., Dalal, S., Webster, N., Rawstron, A., Shingles, J., Newton, D., Cairns, D. A., Glover, P., Grand, T., Warren, H., Bell, S., Girvan, S., Greatorex, N., Hockaday, A., Jackson, S., Phillips, D., Stones, D., Allsup, D., Bloor, A. J. C., …Hillmen, P. Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients. Presented at 65th ASH Annual Meeting And Exposition, San Diego, CA

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study (2023)
Presentation / Conference Contribution
Hillmen, P., Cairns, D. A., Bloor, A. J. C., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J. G., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Howard, D., Hockaday, A., Jackson, S., …Munir, T. Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study. Presented at 65th ASH Annual Meeting and Exposition, San Diego, CA

Introduction: Ibrutinib (I), an irreversible Btk inhibitor, and venetoclax (V), a Bcl-2 inhibitor, improve CLL outcomes in trials compared to chemoimmunotherapy. I and V target two key pathophysiological pathways in CLL and should be synergistic. Thi... Read More about Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study.

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial (2023)
Presentation / Conference Contribution
Rawstron, A., Webster, N., Dalal, S., de Tute, R. M., Bell, S., Cairns, D. A., Girvan, S., Greatorex, N., Hockaday, A., Jackson, S., Phillips, D., Stones, D., Allsup, D., Bloor, A. J. C., Sarma, A., Varghese, A. M., Munir, T., & Hillmen, P. Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. Presented at 65th ASH Annual Meeting and Exposition, San Diego, CA

Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide (2023)
Journal Article
Molica, S., Rossi, M., & Allsup, D. (2023). Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide. Acta Haematologica, 147(3), 257-259. https://doi.org/10.1159/000533349

In addition to the European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) guidelines that are reference standards for the treatment of chronic lymphocytic leukemia (CLL) in Europe and the USA, several consensus... Read More about Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide.

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (2023). Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option. Cancers, 15(14), Article 3737. https://doi.org/10.3390/cancers15143737

Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL). The use of ibrutinib is, howev... Read More about Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial (2023)
Journal Article
Hillmen, P., Pitchford, A., Bloor, A., Broom, A., Young, M., Kennedy, B., Walewska, R., Furtado, M., Preston, G., Neilson, J. R., Pemberton, N., Sidra, G., Morley, N., Cwynarski, K., Schuh, A., Forconi, F., Elmusharaf, N., Paneesha, S., Fox, C. P., Howard, D. R., …Munir, T. (2023). Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The lancet oncology, 24(5), 535-552. https://doi.org/10.1016/S1470-2045%2823%2900144-4

Background: The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludara... Read More about Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies (2023)
Journal Article
Khan, S., Allsup, D., & Molica, S. (2023). An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies. Frontiers in Oncology, 13, Article 1135812. https://doi.org/10.3389/fonc.2023.1135812

Chronic lymphocytic leukaemia (CLL) is a malignancy of clonally expanded antigen-switched, neoplastic, mature B cells. CLL is characterised by a variable degree of immunosuppression and secondary hypogammaglobulinemia. B-cell depleting therapies have... Read More about An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies.

Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol (2023)
Journal Article
Baldwin, Z.-A., Busby, S., Allsup, D., Cohen, J., & Bamidele, O. (2023). Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol. PLoS ONE, 18(3), Article e0282458. https://doi.org/10.1371/journal.pone.0282458

Introduction Haematological malignancies are a heterogenous group of blood and lymphatic cancers. Survivorship care is a similarly diverse term concerning patients’ health and wellbeing from diagnosis to end of life. Survivorship care for patients wi... Read More about Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol.

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL (2022)
Journal Article
Antic, D., Milic, N., Chatzikonstantinou, T., Scarfò, L., Otasevic, V., Rajovic, N., Allsup, D., Alonso Cabrero, A., Andres, M., Baile Gonzales, M., Capasso, A., Collado, R., Cordoba, R., Cuéllar-García, C., Correa, J. G., De Paoli, L., De Paolis, M. R., Del Poeta, G., Dimou, M., Doubek, M., …Stamatopoulos, K. (2022). Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. Journal of Hematology & Oncology, 15(1), Article 116. https://doi.org/10.1186/s13045-022-01333-0

BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immu... Read More about Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.

PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia (2022)
Journal Article
Taynton, T., Barlow, G., & Allsup, D. (2022). PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia. JAC-Antimicrobial Resistance, 4(4), Article dlac074. https://doi.org/10.1093/jacamr/dlac074

Mould-active antifungal prophylaxis is frequently used to prevent invasive fungal infection in patients with acute leukaemia being treated with intensive chemotherapy. Invasive fungal infections are difficult to diagnose, and despite the use of proph... Read More about PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia.